II
RARE icon

Ishara Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ishara Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.84M Buy
205,000
+30,750
+18% +$764K 5.03% 5
2026
Q1 		$3.65M Buy
174,250
+124,250
+249% +$2.8M 3.46% 9
2025
Q4 		$1.15M Buy
+50,000
New +$1.64M 1.32% 27

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ishara Investments's RARE Position: Q2 2026 in Review

Ishara Investments increased its Ultragenyx Pharmaceutical (RARE) stake by 18% in Q2 2026, buying an estimated $764K and bringing the position to 205,000 shares worth $6.84M. The position accounts for 5.03% of the portfolio, ranked #5.

Ishara Investments first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Ishara Investments held 205,000 shares of Ultragenyx Pharmaceutical worth $6.84M as of Q2 2026.
  • Ishara Investments bought 30,750 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $764K.
  • Ultragenyx Pharmaceutical made up 5.03% of Ishara Investments's portfolio in Q2 2026, its #5 holding.
  • Ishara Investments first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Ishara Investments's 13F filing for Q2 2026, filed 14 Aug 2026.